Xellia
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Xellia ApS is a Danish multinational pharmaceutical and life sciences company headquartered in Copenhagen specialized in the production of anti-biotics, including Vancomycin and Bacitracin. The company's US base of operations is in Buffalo Grove, Illinois, with additional facilities in Ohio, and North Carolina. In 2018, Xellia's sales in the United States accounted for 60% of its total revenue.
Xellia ApS is a Danish multinational pharmaceutical and life sciences company headquartered in Copenhagen specialized in the production of anti-biotics, including Vancomycin and Bacitracin. The company's US base of operations is in Buffalo Grove, Illinois, with additional facilities in Ohio, and North Carolina. In 2018, Xellia's sales in the United States accounted for 60% of its total revenue.
Partnerships
In 2019, Xellia partnered with Civica Rx to produce generic Vancomycin and Daptomycin. The partnership's stated aim is to remedy chronic drug shortages that have affected the American pharmaceutical market.
China-US Trade War
Xellia has been discussed as a potential alternative to Chinese companies for anti-biotic primary ingredients in the context of the China-United States trade war.
See also
List of Danish companies List of pharmaceutical companies
Text derived from https://en.wikipedia.org/w/index.php?oldid=1359941797 under CC BY-SA 4.0; modifications have been made.